Advances in HCV: A Clinical Trial Update from EASL 2008 CME

Author Information and Disclosures

Release Date: June 9, 2008; Valid for credit through June 9, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This CME activity, “Advances in HCV: A Clinical Trial Update from EASL 2008,” is based on the original presentation of April 27, 2008, in Milan, Italy, and adapted for release on Medscape.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 DIME
Roche
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Critically discuss significant findings from clinical trials and their clinical implications for patients with chronic HCV infection.
  2. Evaluate efficacy and safety data of emerging treatment strategies for HCV.
  3. Integrate study results into clinical practice to improve outcomes in patients with chronic HCV.
Authors and Disclosures

Douglas T. Dieterich, MD
Disclosure: Research: Roche, Gilead, Bristol-Myers Squibb, Boehringer Ingelheim, Schering; Consultant: Roche, Gilead, Bristol-Myers Squibb, Boehringer Ingelheim; Speaker’s Bureau: Roche, Gilead, Bristol-Myers Squibb, Schering. Dr. Dieterich has disclosed that he will reference unlabeled/unapproved used of boceprevir, telaprevir, R7128, R1626, and albinterferon alfa-2b.


Michael W. Fried, MD
Disclosure: Research: Roche, Vertex, Human Genome, Wyeth, Gilead; Consultant: Roche, Tibotec, Pharmasset; Stockholder: Pharmasset. Dr. Fried has disclosed that he will not include discussion of off-label use of investigational drugs.


K. Rajender Reddy, MD
Disclosure: Consultant: Roche; Research: Roche; Speaker’s Bureau: Roche. Dr. Reddy has disclosed that he will reference unlabeled/unapproved used of taribavirin.

 
Discovery Institute of Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Discovery Institute of Medical Education (DIME). DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DIME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.